Dapagliflozin as monotherapy in drug-naive asian patients with type 2 diabetes mellitus: A randomized, blinded, prospective phase III study

Clinical Therapeutics

Volumn 36, Issue 1, 2014, Pages

  Ji, Linong ^a   Ma, Jianhua ^b   Li, Hongmei ^c   Mansfield, Traci A ^c   T'Joen, Caroline L ^c   Iqbal, Nayyar ^c   Ptaszynska, Agata ^c   List, James F ^c  

^a PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

^b THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^c BRISTOL MYERS SQUIBB   (United States)

Author keywords

Asian; dapagliflozin; glycemic control; monotherapy; SGLT2; type 2 diabetes mellitus

Indexed keywords

DAPAGLIFLOZIN; GLUCOSE; HEMOGLOBIN A1C; PLACEBO;

ADULT; ARTICLE; ASIAN; BACKACHE; BALANOPOSTHITIS; BODY WEIGHT; CHINESE; CONSTIPATION; CONTROLLED STUDY; COUGHING; DIABETIC NEPHROPATHY; DIARRHEA; DIET; DISEASE DURATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EXERCISE; FEMALE; FUNGAL GENITAL INFECTION; GASTRITIS; GENITAL TRACT INFECTION; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; KIDNEY DISEASE; KIDNEY FAILURE; KIDNEY INFECTION; MAJOR CLINICAL STUDY; MALE; MALE GENITAL SYSTEM DISEASE; MICTURITION DISORDER; MIDDLE AGED; MONOTHERAPY; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PHASE 3 CLINICAL TRIAL; PYELONEPHRITIS; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; THROMBOCYTOPENIA; TOOTH PAIN; UNSPECIFIED SIDE EFFECT; URETHRITIS; URINARY TRACT INFECTION; VAGINA MYCOSIS; VAGINITIS;

ASIAN; DAPAGLIFLOZIN; GLYCEMIC CONTROL; MONOTHERAPY; SGLT2; TYPE 2 DIABETES MELLITUS;

ADULT; ASIAN CONTINENTAL ANCESTRY GROUP; BLOOD GLUCOSE; BODY WEIGHT; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; GLUCOSIDES; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; REPRODUCTIVE TRACT INFECTIONS; TREATMENT OUTCOME; URINARY TRACT INFECTIONS;

EID: 84892368256     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2013.11.002     Document Type: Article

References (43)

1. National Diabetes Research Group A mass survey of diabetes mellitus in a population of 300,000 in 14 provinces and municipalities in China Zhonghua Nei Ke Za Zhi 11 1981 678 683
2. W. Yang, J. Lu, and J. Weng et al. Prevalence of diabetes among men and women in China N Engl J Med 362 2010 1090 1101
3. D. Zhao, F. Zhao, and Y. Li et al. Projected and observed diabetes epidemics in China and beyond Curr Cardiol Rep 14 2012 106 111
4. W. Yu, C. Hu, and W. Jia Genetic advances of type 2 diabetes in Chinese populations J Diabetes 4 2012 213 220
5. L. Ji, D. Hu, and C. Pan et al. Primacy of the 3B approach to control risk factors for cardiovascular disease among type 2 diabetes Am J Med 126 2013 925.e11 925.e22
6. S.E. Inzucchi, R.M. Bergenstal, and J.B. Buse et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) Diabetes Care 35 2012 1364 1379
7. B. Komoroski, N. Vachharajani, and D. Boulton et al. Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects Clin Pharmacol Ther 85 2009 520 526
8. B. Komoroski, N. Vachharajani, and Y. Feng et al. Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus Clin Pharmacol Ther 85 2009 513 519
9. C.J. Bailey, J.L. Gross, and A. Pieters et al. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial Lancet 375 2010 2223 2233
10. E. Ferrannini, S.J. Ramos, and A. Salsali et al. Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial Diabetes Care 33 2010 2217 2224
11. R.R. Henry, A.V. Murray, and M.H. Marmolejo et al. Dapagliflozin, metformin XR, or both: initial pharmacotherapy for type 2 diabetes, a randomised controlled trial Int J Clin Pract 66 2012 446 456
12. J.F. List, V. Woo, and E. Morales et al. Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes Diabetes Care 32 2009 650 657
13. M.A. Nauck, S. Del Prato, and J.J. Meier et al. Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial Diabetes Care 34 2011 2015 2022
14. K. Strojek, K.H. Yoon, and V. Hruba et al. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial Diabetes Obes Metab 13 2011 928 938
15. J. Rosenstock, M. Vico, and L. Wei et al. Effects of dapagliflozin, an SGLT2 inhibitor, on HbA(1c), body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy Diabetes Care 35 2012 1473 1478
16. Jabbour S, Hardy E, Sugg JE, et al. Dapagliflozin as add-on therapy to sitagliptin with or without metformin: a randomized, double-blind, placebo-controlled study. Presented at: the 72nd Scientific Sessions of the American Diabetes Association; June 8-12, 2012; Philadelphia, Pa. 1071-P.
17. J.P. Wilding, V. Woo, and N.G. Soler et al. Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial Ann Intern Med 156 2012 405 415
18. S. Kasichayanula, X. Liu, and S.C. Griffen et al. Effects of rifampin and mefenamic acid on the pharmacokinetics and pharmacodynamics of dapagliflozin Diabetes Obes Metab 15 2013 280 283
19. M. Obermeier, M. Yao, and A. Khanna et al. In vitro characterization and pharmacokinetics of dapagliflozin (BMS-512148), a potent sodium-glucose cotransporter type II inhibitor, in animals and humans Drug Metab Dispos 38 2010 405 414
20. L. Yang, H. Li, and A. Bui et al. Pharmacokinetic and pharmacodynamic properties of single- and multiple-dose of dapagliflozin, a selective inhibitor of SGLT2, in healthy Chinese subjects Clin Ther 35 2013 1211 1222
21. K. Kaku, S. Inoue, and O. Matsuoka et al. Efficacy and safety of dapagliflozin as a monotherapy for type 2 diabetes mellitus in Japanese patients with inadequate glycaemic control: a phase II multicentre, randomized, double-blind, placebo-controlled trial Diabetes Obes Metab 15 2013 432 440
22. J. Bolinder, O. Ljunggren, and J. Kullberg et al. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin J Clin Endocrinol Metab 97 2012 1020 1031
23. V. Woo, A.M. Langkilde, and J. Sugg et al. Dapagliflozin, a novel antihyperglycemic agent that promotes urinary glucose excretion, reduces systolic blood pressure in patients with type 2 diabetes mellitus Circulation 124 2011 A9520
24. World Health Organization Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies Lancet 363 2004 157 163
25. M. Chiu, P.C. Austin, and D.G. Manuel et al. Deriving ethnic-specific BMI cutoff points for assessing diabetes risk Diabetes Care 34 2011 1741 1748
26. F. Razak, S.S. Anand, and H. Shannon et al. Defining obesity cut points in a multiethnic population Circulation 115 2007 2111 2118
27. A. Balasubramanyam, S. McKay, and P. Nadkarni et al. Ethnicity affects the postprandial regulation of glycogenolysis Am J Physiol 277 1999 E905 E914
28. K. Kikuchi, U. Nezu, and J. Shirakawa et al. Correlations of fasting and postprandial blood glucose increments to the overall diurnal hyperglycemic status in type 2 diabetic patients: variations with levels of HbA1c Endocr J 57 2010 259 266
29. J.S. Wang, S.T. Tu, and I.T. Lee et al. Contribution of postprandial glucose to excess hyperglycaemia in Asian type 2 diabetic patients using continuous glucose monitoring Diabetes Metab Res Rev 27 2011 79 84
30. M. Zhang, A.A. Tsiatis, and M. Davidian Improving efficiency of inferences in randomized clinical trials using auxiliary covariates Biometrics 64 2008 707 715
31. B.F. Zhou Predictive values of body mass index and waist circumference for risk factors of certain related diseases in Chinese adults - study on optimal cut-off points of body mass index and waist circumference in Chinese adults Biomed Environ Sci 15 2002 83 96
32. C.J. Bailey, N. Iqbal, and C. T'Joen et al. Dapagliflozin monotherapy in drug-naive patients with diabetes: a randomized-controlled trial of low-dose range Diabetes Obes Metab 14 2012 951 959
33. J.P. Wilding, P. Norwood, and C. T'Joen et al. A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: applicability of a novel insulin-independent treatment Diabetes Care 32 2009 1656 1662
34. K. Stenlöf, W.T. Cefalu, and K.A. Kim et al. Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise Diabetes Obes Metab 15 2013 372 382
35. Mudaliar S, Henry R, Boden G, et al. Changes in insulin sensitivity as measured by glucose disposal rate and acute insulin secretion with the sodium glucose co-transporter 2 inhibitor dapagliflozin. Presented at: the 47th Scientific Sessions of the European Association for the Study of Diabetes; September 12-16, 2011; Lisbon, Portugal. Abstract 854.
36. K. Rohwedder, V. Hruba, and S. Salsali et al. Dapagliflozin, a sodium-glucose cotransporter 2 inhibitor, has a low propensity to cause hypoglycemia in patients with type 2 diabetes Diabetes Care 60 Suppl 1 2011 A286
37. N.J. Bohannon Treatment of vulvovaginal candidiasis in patients with diabetes Diabetes Care 21 1998 451 456
38. S.L. Chen, S.L. Jackson, and E.J. Boyko Diabetes mellitus and urinary tract infection: epidemiology, pathogenesis and proposed studies in animal models J Urol 182 2009 S51 S56
39. G.G. Donders Lower genital tract infections in diabetic women Curr Infect Dis Rep 4 2002 536 539
40. A. Ronald, and E. Ludwig Urinary tract infections in adults with diabetes Int J Antimicrob Agents 17 2001 287 292
41. B.R. Shah, and J.E. Hux Quantifying the risk of infectious diseases for people with diabetes Diabetes Care 26 2003 510 513
42. V. Vallon, and K. Sharma Sodium-glucose transport: role in diabetes mellitus and potential clinical implications Curr Opin Nephrol Hypertens 19 2010 425 431
43. P. Nyirjesy, Y. Zhao, and K. Ways et al. Evaluation of vulvovaginal symptoms and Candida colonization in women with type 2 diabetes mellitus treated with canagliflozin, a sodium glucose co-transporter 2 inhibitor Curr Med Res Opin 28 2012 1173 1178